EUVIMEDEUVIMED entdecken
Open Access

Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters

Palash Sharma iD, Milind A Phadnis iD

Pharmaceutical Statistics · 2025

DOI: 10.1002/pst.2429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von Palash Sharma und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase II as Topic, Research Design. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Center Support Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stochastic curtailment tests for Phase II two‐arm trials with time‐to‐event end points are traditionally performed using the log‐rank test. Recent advances in designing time‐to‐event trials have utilized the Weibull distribution with a known shape parameter estimated from historical studies. As sample size calculations depend on the value of this shape parameter, these methods either cannot be used or likely underperform/overperform when the natural variation around the point estimate is ignored. We demonstrate that when the magnitude of the Weibull shape parameters changes, unblinded interim information on the shape of the survival curves can be useful to enrich the final analysis for reestimation of the sample size. For such scenarios, we propose two Bayesian solutions to estimate the natural variations of the Weibull shape parameter. We implement these approaches under the framework of the newly proposed relative time method that allows nonproportional hazards and nonproportional time. We also demonstrate the sample size reestimation for the relative time method using three different approaches (internal pilot study approach, conditional power, and predictive power approach) at the interim stage of the trial. We demonstrate our methods using a hypothetical example and provide insights regarding the practical constraints for the proposed methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase II as TopicResearch DesignSample SizeHumansStochastic ProcessesBayes TheoremTime FactorsModels, Statistical

Stichwörter der Autor:innen

Weibull distributionnonproportional hazardsrelative timesample size reestimationstochastic curtailment teststime‐to‐event

Autor:innen und Institutionen

  • Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.

ORCID-Profile: Palash Sharma, Milind A Phadnis

Förderung

  • NCI NIH HHS
  • Cancer Center Support Grant

Zitieren

APA

Sharma, P., & Phadnis, M. A. (2025). Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2429

Vancouver

Sharma P, Phadnis MA. Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters. Pharmaceutical Statistics. 2025. doi:10.1002/pst.2429

BibTeX
@article{Sharma2025,
  author = {Sharma, Palash and Phadnis, Milind A},
  title = {Sample Size Reestimation in Stochastic Curtailment Tests With Time‐to‐Events Outcome in the Case of Nonproportional Hazards Utilizing Two Weibull Distributions With Unknown Shape Parameters},
  journal = {Pharmaceutical Statistics},
  year = {2025},
  doi = {10.1002/pst.2429}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche